GlassScriptPhysician profile
Salwa S Ayad
NPI 1154396984
$2,163.63
in general payments reported to CMS, 2019-2025
17 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $109 · 2021: $287 · 2022: $414 · 2023: $323 · 2024: $251 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $880.40 | 2019-2024 | Freestyle Libre 3 |
| Insulet Corporation | $459.82 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $209.98 | 2024-2025 | Korlym |
| Medtronic, INC. | $103.29 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $78.72 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $77.72 | 2019-2025 | Mounjaro |
| Astellas Pharma US INC | $61.00 | 2023-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $50.72 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.14 | 2022-2025 | |
| Mannkind Corporation | $28.75 | 2019-2020 | |
| Amgen INC. | $28.20 | 2019 | |
| Abbvie INC. | $27.10 | 2022-2024 | |
| Ionis Pharmaceuticals, INC. | $26.34 | 2025 | Tryngolza |
| Boston Scientific Corporation | $24.76 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.41 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $18.46 | 2025 | Xyosted |
| Radius Health, INC. | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salwa Ayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.